Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 ...

Envista Holdings Corporation ("Envista") today announced that the company will participate in a fireside chat at the Evercore HealthCONx Conference on Tuesday, December 3, 2024 from 12:30 ? 1:15 pm ET ...

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Cardiometabolic disease biotech NeuroBo Pharmaceuticals is shaking up its corporate image with a complete rebrand. | ...

A recent study from the Federal University of São Paulo (UNIFESP) has found that using infrared light along with regular ...

Background and Aims: Neuropathy in association with chronic liver disease, including cirrhosis, is recognized; however, there are differences in the incidence and type of neuropathy reported.

Table 1. Dosage Adjustment, Targeted Dosages, Interactions, and Adverse Effects of Medications Commonly Used to Treat Diabetic Neuropathy a,b,c ...

Since potentially neurotoxic drugs are widely used for tumors of higher incidence ... chemotherapy- IPN is often an adverse event of the treatment which may limit its administration and a new ...

(AP Photo) WASHINGTON (AP) — Those ever-present TV drug ads showing patients hiking, biking or enjoying a day at the beach could soon have a different look: New rules require drugmakers to be clearer ...